Prevalencia de quejas subjetivas de memoria: estudio poblacional en España / Prevalence of subjective memory complaints: Population study in Spain

Introducción Las quejas subjetivas de memoria (QSM) pueden ser una señal inicial de un posterior deterioro de las funciones cognitivas. Sin embargo, no se han publicado estudios poblacionales cubriendo toda España para conocer la prevalencia de las QSM. El objetivo del presente estudio fue conocer la prevalencia de las QSM en la población general residente en España >50 años y, también qué actuaciones se llevaban a cabo al respecto. Materiales y métodos Se realizaron entrevistas mediante un cuestionario online/Computer Assisted Web Interview (CAWI) a una muestra representativa a nivel nacional >50 años. La encuesta constaba de 34 ítems divididos en 2 bloques. Se consideró presencia de QSM cuando en la pregunta 1 el sujeto contestaba que ‘Sí’ tenía algún problema de memoria. Resultados Se entrevistó a 2.300 personas (53,7% mujeres; 23,9% ≥75 años). El 31% contestaron que consideraban que tenían un problema de memoria (sin diferencias entre sexos, media de tiempo con problemas de memoria de 3,0 años). Se observó mayor prevalencia de QSM en ≥75 años (44%). El 90% no incluían ningún alimento específico en su dieta para sus problemas de memoria, y tampoco estaban tomando productos farmacéuticos, complementos de la dieta o suplementos nutricionales (92%). El 78% de los entrevistados con QSM no han consultado a profesionales sanitarios por sus problemas de memoria. Conclusiones Las QSM tienen una prevalencia considerable en nuestro medio, afectando a casi un tercio de los individuos >50 años. La mayoría de los entrevistados con quejas de memoria no buscó el consejo/recomendación de profesionales sanitarios con respecto a las mismas. (AU)

Introduction Subjective memory complaints (SMC) might be an early sign of further deterioration in cognitive functions. However, no population studies have been published covering all Spain to determine the SMC prevalence. The objective of the present study was to determine the SMC prevalence in the general population residing in Spain >50 years of age and also which related actions were done. Materials and methods Interviews were conducted with a nationally representative sample >50 years of age using an online/computer assisted web interview (CAWI) questionnaire. The survey consisted of 34 items divided into two blocks. Presence of SMC was considered when in question 1 the subject answered that “Yes” he had some memory problem. Results Two thousand three hundred people (53.7% women; 23.9% ≥75 years old) were interviewed. 31% answered that they considered they had a memory problem (no differences between sexes, mean time with memory problems of 3.0 years). A higher prevalence of SMC was observed in ≥75 years old (44%). 90% did not include any specific foods in their diet for their memory problems, neither were taking any pharmaceuticals, diet supplements or nutritional supplements (92%). 78% of those interviewed with SMC have not consulted health professionals for their memory problems. Conclusions SMC are considerably prevalent in our environment affecting almost a third of people ≥50 years of age. Most of the interviewees with SMC did not go to health professionals to manage their SMC. (AU)

Prevalencia de quejas subjetivas de memoria: estudio poblacional en España / Prevalence of subjective memory complaints: Population study in Spain

Introducción Las quejas subjetivas de memoria (QSM) pueden ser una señal inicial de un posterior deterioro de las funciones cognitivas. Sin embargo, no se han publicado estudios poblacionales cubriendo toda España para conocer la prevalencia de las QSM. El objetivo del presente estudio fue conocer la prevalencia de las QSM en la población general residente en España >50 años y, también qué actuaciones se llevaban a cabo al respecto. Materiales y métodos Se realizaron entrevistas mediante un cuestionario online/Computer Assisted Web Interview (CAWI) a una muestra representativa a nivel nacional >50 años. La encuesta constaba de 34 ítems divididos en 2 bloques. Se consideró presencia de QSM cuando en la pregunta 1 el sujeto contestaba que ‘Sí’ tenía algún problema de memoria. Resultados Se entrevistó a 2.300 personas (53,7% mujeres; 23,9% ≥75 años). El 31% contestaron que consideraban que tenían un problema de memoria (sin diferencias entre sexos, media de tiempo con problemas de memoria de 3,0 años). Se observó mayor prevalencia de QSM en ≥75 años (44%). El 90% no incluían ningún alimento específico en su dieta para sus problemas de memoria, y tampoco estaban tomando productos farmacéuticos, complementos de la dieta o suplementos nutricionales (92%). El 78% de los entrevistados con QSM no han consultado a profesionales sanitarios por sus problemas de memoria. Conclusiones Las QSM tienen una prevalencia considerable en nuestro medio, afectando a casi un tercio de los individuos >50 años. La mayoría de los entrevistados con quejas de memoria no buscó el consejo/recomendación de profesionales sanitarios con respecto a las mismas. (AU)

Introduction Subjective memory complaints (SMC) might be an early sign of further deterioration in cognitive functions. However, no population studies have been published covering all Spain to determine the SMC prevalence. The objective of the present study was to determine the SMC prevalence in the general population residing in Spain >50 years of age and also which related actions were done. Materials and methods Interviews were conducted with a nationally representative sample >50 years of age using an online/computer assisted web interview (CAWI) questionnaire. The survey consisted of 34 items divided into two blocks. Presence of SMC was considered when in question 1 the subject answered that “Yes” he had some memory problem. Results Two thousand three hundred people (53.7% women; 23.9% ≥75 years old) were interviewed. 31% answered that they considered they had a memory problem (no differences between sexes, mean time with memory problems of 3.0 years). A higher prevalence of SMC was observed in ≥75 years old (44%). 90% did not include any specific foods in their diet for their memory problems, neither were taking any pharmaceuticals, diet supplements or nutritional supplements (92%). 78% of those interviewed with SMC have not consulted health professionals for their memory problems. Conclusions SMC are considerably prevalent in our environment affecting almost a third of people ≥50 years of age. Most of the interviewees with SMC did not go to health professionals to manage their SMC. (AU)

[Prevalence of subjective memory complaints: Population study in Spain]. / Prevalencia de quejas subjetivas de memoria: estudio poblacional en España.

INTRODUCTION: Subjective memory complaints (SMC) might be an early sign of further deterioration in cognitive functions. However, no population studies have been published covering all Spain to determine the SMC prevalence. The objective of the present study was to determine the SMC prevalence in the general population residing in Spain >50 years of age and also which related actions were done. MATERIALS AND METHODS: Interviews were conducted with a nationally representative sample >50 years of age using an online/computer assisted web interview (CAWI) questionnaire. The survey consisted of 34 items divided into two blocks. Presence of SMC was considered when in question 1 the subject answered that "Yes" he had some memory problem. RESULTS: Two thousand three hundred people (53.7% women; 23.9% ≥75 years old) were interviewed. 31% answered that they considered they had a memory problem (no differences between sexes, mean time with memory problems of 3.0 years). A higher prevalence of SMC was observed in ≥75 years old (44%). 90% did not include any specific foods in their diet for their memory problems, neither were taking any pharmaceuticals, diet supplements or nutritional supplements (92%). 78% of those interviewed with SMC have not consulted health professionals for their memory problems. CONCLUSIONS: SMC are considerably prevalent in our environment affecting almost a third of people ≥50 years of age. Most of the interviewees with SMC did not go to health professionals to manage their SMC.

Bioavailability of Cariban® Capsules: A Modified-Release Fixed-Dose Combination of Doxylamine and Pyridoxine to Relieve Nausea and Vomiting During Pregnancy.

BACKGROUND: Nausea and vomiting is a very prevalent condition during pregnancy. Combination of doxylamine and pyridoxine is placed as first-line pharmacological option for its treatment in most clinical guidelines. Among different release forms available, Cariban® is a fixed-dose combination of doxylamine/pyridoxine 10/10 mg, formulated as modified-release capsules. OBJECTIVES: In the present study, we aimed to characterize the bioavailability performance of Cariban® in vitro and in vivo. METHODS: An in vitro dissolution test was performed to evaluate the release profile of Cariban®, together with immediate- and delayed-release formulations available on the market. A single-center, single-dose, open-label bioavailability study following Cariban® administration in 12 healthy adult female patients was carried out to explore the drug behavior in vivo (protocol NBR-002-13; EUDRA-CT 2013-005422-35). These data were additionally used to perform a computational pharmacokinetic simulation of the posology approved for this drug. RESULTS: Cariban® capsules demonstrate a prolonged-release performance, with an early, gradual, and progressive release of both actives until reaching a complete dissolution after 4-5 h in solution. The pharmacokinetic features of these capsules show that doxylamine and pyridoxine metabolites are early absorbed, being all detectable in plasma within 1 h following oral administration. Computational pharmacokinetic simulation predicts that different posology provides distinct profiles of metabolites in plasma, with 1-1-2 (morning-midafternoon-night) being the one that concentrates higher plasma levels but lower dose dumping for 24 h. CONCLUSION: Cariban® behaves as a prolonged-release formulation, which correlates with rapid absorption and arising of the actives in the plasma, but also long-lasting and sustained bioavailability, especially when administered following the complete posology. These results would underlie its demonstrated efficacy to relieve nausea and vomiting of pregnancy (NVP) under clinical settings.

Bioavailability of Oniria®, a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers.

BACKGROUND: Melatonin is an endogenous substance which plays a key role in sleep induction by reducing sleep onset latency; it has been approved by the European Food Safety Authority as a food supplement for exogenous administration. Oniria® is a food supplement formulated as 1.98 mg of prolonged-release melatonin tablets; it displays a dual dissolution profile in vitro. OBJECTIVES: The main objective of the present study was to evaluate the relative oral bioavailability of Oniria®, in comparison with immediate-release tablets (IRT) with a similar melatonin content as a reference. We also attempted to characterize the circadian rhythm of endogenous melatonin. METHODS: We performed an open-label, cross-over, randomized, phase I clinical study with two sequences and three periods involving 14 healthy volunteers. We characterized the endogenous melatonin circadian profile (period 1) and pharmacokinetics (PK) of both Oniria® and the reference melatonin (periods 2 and 3). RESULTS: Two phases were clearly differentiated in the PK profile of Oniria®. An initial one, from dosing up to 2 h, and a delayed one from 2 to 11 h post-administration. During the initial phase, both melatonin formulations were equivalent, with a Cmax value close to 4000 pg/mL. However, in the delayed phase, Oniria® showed significantly higher melatonin concentrations than the IRT (three times higher at 4-6 h post-administration). Moreover, Oniria® exhibited concentrations above the endogenous melatonin peak of 80 pg/mL for up to 2.5 h versus the reference formulation, potentially suggesting an effect of Oniria®, not only in the induction of sleep, but also in the maintenance. CONCLUSION: Oniria® could be a highly promising food supplement, not only for sleep induction but also for the maintenance of sleep.